Geneviève Plu-Bureau

Geneviève Plu-Bureau

Auto-generated profile, based on publicly available information

Geneviève Plu-Bureau

Gynecological Unit Cochin-Port-Royal Hospital University Paris Cité, Paris, France; Faculty of medicine, Université Paris Cité, Paris, France; Women's Cardiovascular Health care Foundation 22 rue de Londres, 75009, Paris, France; Inserm 1153 Team OPPaLE Port-Royal Hospital Paris, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
AMAlice Martin
Alice Martin
GLGrégory Lailler
Grégory Lailler
YBYannick Béjot
Yannick Béjot
AGAmélie Gabet
Amélie Gabet
CGClémence Grave
Clémence Grave
VOV. Olié
V. Olié
Background and Objectives Despite the potentially devastating effects of pregnancy-related stroke, few studies have examined its incidence by type of stroke. We aimed to study the nationwide incidence rates and recent temporal trends for all types of pregnancy-related stroke and to compare these incidences with stroke incidence in nonpregnant women. Methods We conducted a study of 6,297,698 women aged 15–49 years who gave birth in France between 2010 and 2018 with no history of stroke before pregnancy by collecting data from the French National Health Insurance Information System database. Poisson regression was used to estimate the incidence by types of strokes for the different pregnancy periods and the incidence rate ratio of stroke in pregnant vs nonpregnant French women. Results Among the 6,297,698 women, 1,261 (24.0 per 100,000 person-years) experienced a first ever stroke during, antepartum peripartum, or the first 6 weeks of postpartum. Of the pregnancy-related strokes, 42.9% were ischemic (IS), 41.9% were hemorrhagic (with similar proportion of intracerebral and subarachnoid hemorrhage), and 17.4% were cerebral venous thrombosis (CVT). Compared with nonpregnant women, incidence rates of stroke were similar during pregnancy for IS (adjusted incidence risk ratio [IRR] 0.9 [0.8–1.1]), slightly higher for all hemorrhagic strokes (IRR 1.4 [1.2–1.8]), and considerably increased for CVT (IRR 8.1 [6.5–10.1]). Pregnancy-related stroke incidence rose between 2010 and 2018 for IS and HS but was stable for CVT. Discussion The risk of pregnancy-related CVT was more than 8-fold higher than that observed in nonpregnant women. The incidence of pregnancy-related IS and HS is increasing over time, and efforts should be made for prevention considering treatable cardiovascular risk factors and hypertensive disorders in pregnant women.

16 April 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
GLGrégory Lailler
Grégory Lailler
CGClémence Grave
Clémence Grave
AGAmélie Gabet
Amélie Gabet
PJPierre Joly
Pierre Joly
NRNolwenn Regnault
Nolwenn Regnault
VOV. Olié
V. Olié
Background: We aimed to evaluate the impact of hypertensive disorders of pregnancy occurrence, recurrence, onset time, and severity on mortality and on a wide range of cardiovascular outcomes in France. Methods and Results: CONCEPTION (Cohort of Cardiovascular Diseases in Pregnancy) is a French nationwide prospective cohort using data from the National Health Data System. We included all women in CONCEPTION with no history of a cardiovascular event who delivered in France for the first time between 2010 and 2018 (N=2 819 655). Hypertensive disorders of pregnancy and cardiovascular outcomes during the study follow‐up were identified using algorithms combining International Classification of Diseases, Tenth Revision ( ICD‐10 ) coded diagnoses during hospitalization and purchases of medication between 2010 and 2021. We fitted Cox models with time‐varying exposure to assess the associations of hypertensive disorders of pregnancy with mortality and cardiovascular events. Women with gestational hypertension had a 1.25‐ to 2‐fold higher risk of stroke, acute coronary syndrome, peripheral arterial disease, pulmonary embolism, and chronic kidney disease, and a 2‐ to 4‐fold higher risk of rhythm and conduction disorder and heart failure. Women with preeclampsia had a 1.35‐ to 2‐fold higher risk of rhythm or conduction disorder and pulmonary embolism during follow‐up; a 2‐ to 4‐fold higher risk of stroke, acute coronary syndrome, and peripheral arterial disease; and a 7‐ to 9‐fold higher risk of heart failure and chronic kidney disease. They were 1.8 times more likely to die and 4.4 times more likely to die of cardiovascular causes. Conclusions: Hypertensive disorders of pregnancy drastically increase the risk of mortality, cardiovascular, and renal events early after pregnancy. Recurrent, severe, and early‐onset preeclampsia further increases this risk.

3 April 2018 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
JHJustine Hugon-Rodin
Justine Hugon-Rodin
MHMarie-Hélène Horellou
Marie-Hélène Horellou
JCJacqueline Conard
Jacqueline Conard
AGAnne Gompel
Anne Gompel
GPGeneviève Plu-Bureau
Geneviève Plu-Bureau
Objective This article estimates the interaction between types of combined hormonal contraception (CHC) and factor V Leiden (FVL) mutation on the risk of venous thrombosis event (VTE). Subjects and Methods All premenopausal women with first incident VTE who were referred to our unit (Paris, France) between 2000 and 2009 were included in this case-only study. Differences in interactions by progestin type were assessed on a multiplicative scale, assuming the independence of genotype and prescription of type of CHC. Results Among 2,613 women with VTE, 15.9% had a FVL and 69% used CHC. The interaction between CHC use and presence of FVL on VTE risk was statistically significant (1.37, 1.06–1.77 95% confidence interval [CI]). This interaction appeared higher for drospirenone 1.99 (1.18–3.38 95% CI) (n = 98) or cyproterone acetate users 1.71 (1.20–2.45 95% CI) (n = 326), but not significant for 1st or 2nd or norgestimate CHC users. The results were similar when excluding women with a family history of VTE or with provoked VTE. In this sub-group of women, these interactions appeared higher for third generation, cyproterone acetate and drospirenone CHC users as compared with 1st or 2nd or norgestimate CHC users (odds ratio [OR], 1.68 [1.04–2.70; 95% CI], 2.91 [1.71–4.95 95% CI], 3.22 [1.54–6.73 95% CI], respectively). Conclusion Our results show that the interaction between FVL and CHC use differ by progestin type, which is higher in CHC containing third-generation progestin, drospirenone or cyproterone acetate, compared with second generation. Further studies are needed to assess the cost-effectiveness of biological thrombophilia screening (FVL) when such prescription of CHC is planned.

19 January 2022 in Reproductive BioMedicine Online
Verified
Journal Article
Closed access
MMManon MANGIARDI
Manon MANGIARDI
CSClara Sebbag
Clara Sebbag
CRChristine Rousset-Jablonski
Christine Rousset-Jablonski
IRIsabelle Ray-Coquard
Isabelle Ray-Coquard
CBClémentine Berkach
Clémentine Berkach
AHAnne Sophie Hamy
Anne Sophie Hamy

6 September 2022 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
TSThomas Samoyeau
Thomas Samoyeau
CPCorentin Provost
Corentin Provost
ARAlexandre Roux
Alexandre Roux
LLLaurence Legrand
Laurence Legrand
EDEdouard Dezamis
Edouard Dezamis
JBJoseph Benzakoun
Joseph Benzakoun

7 March 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
GLGrégory Lailler
Grégory Lailler
CGClémence Grave
Clémence Grave
AGAmélie Gabet
Amélie Gabet
NRNolwenn Regnault
Nolwenn Regnault
CDCatherine Deneux‐Tharaux
Catherine Deneux‐Tharaux
VOV. Olié
V. Olié
Background: It has been suggested that chronic hypertension is a risk factor for negative maternal and fetal outcomes during pregnancy and postpartum. We aimed to estimate the association of chronic hypertension on adverse maternal and infant outcomes and assess the impact of antihypertensive treatment and these outcomes. Methods and Results: Using data from the French national health data system, we identified and included in the CONCEPTION cohort all women in France who delivered their first child between 2010 and 2018. Chronic hypertension before pregnancy was identified through antihypertensive medication purchases and by diagnosis during hospitalization. We assessed the incidence risk ratios (IRRs) of maternofetal outcomes using Poisson models. A total of 2 822 616 women were included, and 42 349 (1.5%) had chronic hypertension and 22 816 were treated during pregnancy. In Poisson models, the adjusted IRR (95% CI) of maternofetal outcomes for women with hypertension were as follows: 1.76 (1.54–2.01) for infant death, 1.73 (1.60–1.87) for small gestational age, 2.14 (1.89–2.43) for preterm birth, 4.58 (4.41–4.75) for preeclampsia, 1.33 (1.27–1.39) for cesarean delivery, 1.84 (1.47–2.31) for venous thromboembolism, 2.62 (1.71–4.01) for stroke or acute coronary syndrome, and 3.54 (2.11–5.93) for maternal death postpartum. In women with chronic hypertension, being treated with an antihypertensive drug during pregnancy was associated with a significantly lower risk of obstetric hemorrhage, stroke, and acute coronary syndrome during pregnancy and postpartum. Conclusions: Chronic hypertension is a major risk factor of infant and maternal negative outcomes. In women with chronic hypertension, the risk of pregnancy and postpartum cardiovascular events may be decreased by antihypertensive treatment during pregnancy.